Effect of polycmorphism in plasminogen activate inhavitor on the occunence ofcardiac complication in Kawasaki disease

纤溶酶原激活因子多态性对川崎病心脏并发症发生的影响

• 批准号: 12670800
• 负责人: SHIRAHATA Akira
• 金额: $ 2.11万
• 依托单位: University of Occupational and Environmental Health
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2001
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-12670800/
• 关键词: Kawasaki desease; polymorphism; tissue plasminogen activator; plasminogen activator; cardiac complication; プラスミノゲン・アクチベーター・インヒビター

1.Time course of fibrinolytic system in patients with Kawasaki disease (KD) during acute phase.To determine whether the fibrinolytic system is related to the occurrence of cardiac ccmplication in KD, we measured tissue plasminogen activator (1PA), plasminogen activator inhibitor-1 (PAI-1), and related factors in the plasma of children with KD. TPA and PAI-1 were increased in acute phase. Ch the other hand, TPA/lPAI-1 ratio was lower in the cardiac complication group than in the no ccmplication group throughout the observation period These results indicate that a low fibrinolytic activity may be related to the occurrence of cardiac Duplication in KD.2.Polymorphism in PAI-1 in KDPAI-1 polymorphismwas investigated in patients with KD and controls. Genotype (4G, 5G allele of PAI-1gene) was determined, using PCR assays based on published method The distribution of 4G/4G, 4G/5G and 5G/5G genotype was similar in KD and control. On the other hand, weak association of homozygote of 4G with no cardiac ccmplication were observed in KD. These results provide preliminary evidence that polymorphism in PAI-1 does not contribute to occurrence of KD and cardiac complication in KD.

1.急性期川崎疾病（KD）患者的纤维蛋白水解系统的时间过程。确定纤维蛋白水解系统是否与KD中心脏CCMPLICATION的发生有关，我们测量了组织纤溶酶原激活剂（1PA），质膜激活剂抑制剂-1（PAI-1）（PAI-1）（PAI-1）（PAI-1）和相关因子与KD型浆中的纤溶酶原激活剂抑制剂-1（PAI-1）。 TPA和PAI-1在急性期增加。另一方面，心脏并发症组中TPA/LPAI-1的比率低于整个观察期的NO CCMPLICATION组，这些结果表明，低纤维蛋白分解活性可能与KD.2中的心脏重复发生有关。2。KDPAI-1 POLMORPHISPISPISPAI-1 pAI-1中的POI-1的发生kdpai-1 polymorphismphismorphismorphistimplist和对照kD的患者进行了调查。基因型（4G，PAI-1GENE的5G等位基因）使用基于公开方法的PCR分析确定4G/4G，4G/5G和5G/5G基因型的分布在KD和对照中相似。另一方面，在KD中观察到了4G纯合子的弱关联，没有心脏。这些结果提供了初步证据，表明PAI-1中的多态性并不导致KD中的KD和心脏并发症发生。

项目成果

白幡 聡: "紫斑・出血傾向"小児科診療. 64・11. 1766-1772 (2001)

白畑聪：“紫癜/出血倾向”儿科 64・11（2001）。

Yoshioka A., Shima M., Fukutake K., Takamatsu J., Shirahata A., et al.: "Safety and efficacy of a new recombinant FVIII formulated with sucrose (rFVII-FS) in patients with haemophilia A : a long-term, multtcentre clinical study in Japan"Haemophilia. 7. 24

Yoshioka A.、Shima M.、Fukutake K.、Takamatsu J.、Shirahata A. 等人：“用蔗糖配制的新型重组 FVIII (rFVII-FS) 在血友病 A 患者中的安全性和有效性：

Sakai M, Shirahata A et al.: "Low TPA relative to PAI-1 as a marker of cardiac complication in children with Kawasaki disease"Clin Appl Thrombosis/Hemostasis. 7・3. 214-218 (2001)

Sakai M、Shirahata A 等：“相对于 PAI-1 的低 TPA 作为川崎病儿童心脏并发症的标志物”Clin Appl Thrombosis/Hemostasis 7·3 (2001)。

酒井道生, 白幡 聡: "抗血小板療法の基礎と臨床"小児科診療. 64・8. 1175-1181 (2001)

Michio Sakai，Satoshi Shirahata：“抗血小板治疗的基础和临床实践”儿科学 64・8（2001）。

白幡 聡: "小児の出血傾向の診断と治療の進め方"日本医事新報. 4020. 19-26 (2001)

白畑聪：“如何进行儿童出血倾向的诊断和治疗”日本医学报。 4020. 19-26 (2001)。